High-dose etoposide marrow transplantation Etoposide underwent conventional Phase dose-limiting toxicity studies mild myelosuppression toxicities infrequent degree myelosuppression standard doses approach advantage steep dose-response relationship chemotherapeutic agents etoposide vitro clinical studies etoposide ideal agent dose-escalation studies wide range clinical antitumor activity standard doses steep dose-response curve bone marrow suppression nonmyeloid side effects high-dose etoposide studies intensive hematologic supportive care trials autologous marrow transplantation etoposide single agent high-dose trials mucositis degree hepatic dysfunction dose-limiting maximum tolerated dose MTD setting Multi-agent Phase etoposide cyclophosphamide total body irradiation carmustine carboplatin dose-limiting mucosal toxicity liver lung problems high-dose etoposide toxicity MTD schedule administration Etoposide continuous intravenous infusion doses mg/kg cyclophosphamide similar toxicity marrow support antitumor results lymphomas stage treatment solid tumors treatment patients sensitive relapses outcome Lymphoma patients response rate overall long-term years disease-free survival Germ cell tumors responsive pattern sensitive relapses improvement patients patients year breast cancer small cell lung cancer SCLC high-dose etoposide-containing regimens standard therapy results settings good breast cancer disease-free survival years SCLC years 